Skip to main content
SpringerLink
Log in

Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?

  • Assisted Reproduction
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose: This study was performed to evaluate whether a lower dose (0.2 mg) of cetrorelix would prevent premature LH surge in patients undergoing controlled ovarian hyperstimulation. Methods: Controlled ovarian hyperstimulation was carried out in 45 patients, starting on menstrual cycle day 3 with recombinant FSH (r-FSH), and a cetrorelix of 0.2 mg was administered from day 5 evening of ovarian stimulation until the day before hCG injection. Results: There was a statistically significant decrease in serum LH level one day after the first cetrorelix injection and on the day of hCG administration. Serum LH concentrations were maintained constantly low during the follicular phase with no premature LH surge occurring in any of the patients. Clinical pregnancy was achieved for 18 women (40%), with one of these experiencing intrauterine fetal death before 12 week' gestation. Conclusion: This study demonstrates that a daily dose of cetrorelix 0.2 mg is able to prevent premature LH surge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D: Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788–91.

    Google Scholar 

  2. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P: Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997;67:917–22.

    Article  Google Scholar 

  3. Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P, Diedrich K: Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15:1015–20.

    Article  Google Scholar 

  4. Al-Inany H, Aboulghar M: GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874–85.

    Google Scholar 

  5. Hernandez ER: Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000;15:1211–16.

    Google Scholar 

  6. Ganirelix Dose-Finding Study Group: A double-blind, randomized, dose-finding study to assess the efficacy of the GnRH antagonist Ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone. Hum Reprod 1998;13:3023–31.

    Google Scholar 

  7. Felberbaum R, Reissmann T, Kupker W, Al-Hasani S, Bauer O, Schill T, Zoll C, Diedrich C, Diedrich K: Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J Assist Reprod Genet 1996;13:216–22.

    Article  Google Scholar 

  8. Raga F, Casan EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML: The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 1999;140:3705–12.

    Article  Google Scholar 

  9. Seelig AS, Al-Hasani S, Katalinic A, Schopper B, Sturm R, Diedrich K, Ludwig M: Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 2002;77:472–75.

    Article  Google Scholar 

  10. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, Itskovitz-Eldor J: High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod 1999;14:2242–44.

    Article  Google Scholar 

  11. Dong KW, Marcelin K, Hsu MI, Chiang CM, Hoffman G, Roberts JL: Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue. Mol Hum Reprod 1998;4:893–98.

    Article  Google Scholar 

  12. Engel JB, Riethmuller-Winzen H, Diedrich K: Extrapituitary effects of GnRH antagonists in assisted reproduction: a review. Reprod Biomed Online 2005;10:230–34.

    Article  Google Scholar 

  13. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P: Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526–31.

    Google Scholar 

  14. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI: Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed online 2005;10:567–70.

    Google Scholar 

  15. Hwang JL, Huang LW, Hsieh BC, Tsai YL, Huang SC, Chen CY, Hsieh ML, Chen PH, Lin YH: Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod 2003;18:45–9.

    Article  Google Scholar 

  16. Hardy RI, Tummon IS, Hosseinzadeh M: Luteinizing hormone (LH) surge on ganirelix (Antagon) is related to body mass index (BMI). Fertil Steril 2001;73:178–79.

    Google Scholar 

  17. Engel JB, Ludwig M, Junge K, Howles CM, Diedrich K: No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols. Reprod Biomed Online 2003;6:482–87.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95 Wen Chang Road, Shih Lin District, Taipei, 111, Taiwan

    Heng-Ju Chen, Yu-Hung Lin, Bih-Chwen Hsieh, Kok-Min Seow & Jiann-Loung Hwang

  2. College of Medicine, Fu Jen Catholic University, Sinchuang City, Taipei County, Taiwan

    Heng-Ju Chen, Yu-Hung Lin, Bih-Chwen Hsieh & Jiann-Loung Hwang

  3. Department of Obstetrics and Gynecology, Taipei Medical University, Taipei, Taiwan

    Jiann-Loung Hwang & Chii-Ruey Tzeng

Authors
  1. Heng-Ju Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Hung Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bih-Chwen Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kok-Min Seow
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiann-Loung Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chii-Ruey Tzeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiann-Loung Hwang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, HJ., Lin, YH., Hsieh, BC. et al. Is a lower dose of cetrorelix acetate effective for prevention of LH surge during controlled ovarian hyperstimulation?. J Assist Reprod Genet 23, 289–292 (2006). https://doi.org/10.1007/s10815-006-9054-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-006-9054-0

Keywords

Search

Navigation